NCT01970462

Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Kathleen Dungan · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized controlled trial to determine the safety and efficacy of Sitagliptin in patients with stress hyperglycemia or mild diabetes following cardiac surgery. Patients will receive Sitagliptin or placebo. Sitagliptin may be of particular use in this patient population due to the effects on hepatic glucose production (a major feature of SH), safety (lack of contra-indications for heart failure or renal failure and no hypoglycemia), and tolerability. The secondary objective of this study is to determine whether the management of patients with persistent insulin requirements following cardiac surgery differs among patients with stress hyperglycemia or mild diabetes.

Conditions

• Diabetes Mellitus, Type 2
• Hyperglycemia

Interventions

Type	Name	Description
DRUG	Sitagliptin	Sitagliptin prior to hospital discharge and 6 weeks following discharge.
DRUG	Placebo	Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively

Timeline

• Start date: 2014-01-01
• Primary completion: 2016-08-01
• Completion: 2016-08-01
• First posted: 2013-10-28
• Last updated: 2018-06-18
• Results posted: 2018-05-17

Locations

1 site across 1 country: United States